Comparing the mutation profiles of chronic myeloid leukemia (CML) and AML patients may provide clues as to the mechanisms allowing BCR-ABL TKIs to demonstrate a low incidence of relapse and a long relapse-free latency. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.